Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by $0.09, Bloomberg Earnings reports. Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 63.42%. During the same period in the prior year, the company posted ($0.61) EPS.

Shares of Bellicum Pharmaceuticals (BLCM) traded down 21.242% during trading on Wednesday, reaching $8.435. The company’s stock had a trading volume of 2,838,718 shares. The stock has a 50 day moving average of $11.90 and a 200-day moving average of $12.45. The company’s market capitalization is $279.22 million. Bellicum Pharmaceuticals has a 1-year low of $8.10 and a 1-year high of $23.11.

Several brokerages have commented on BLCM. Ladenburg Thalmann Financial Services set a $31.00 price objective on Bellicum Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, June 24th. Raymond James Financial, Inc. set a $18.00 price objective on Bellicum Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday. Cantor Fitzgerald set a $32.00 price objective on Bellicum Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, June 24th. BidaskClub downgraded Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd. Finally, Jefferies Group LLC cut their price objective on Bellicum Pharmaceuticals from $19.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, May 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $26.86.

In other Bellicum Pharmaceuticals news, CFO Alan A. Musso sold 6,311 shares of Bellicum Pharmaceuticals stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $12.24, for a total value of $77,246.64. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Ken Moseley sold 13,823 shares of Bellicum Pharmaceuticals stock in a transaction on Thursday, July 13th. The shares were sold at an average price of $12.26, for a total value of $169,469.98. Following the completion of the sale, the vice president now owns 14,314 shares in the company, valued at approximately $175,489.64. The disclosure for this sale can be found here. Insiders sold 30,571 shares of company stock worth $367,295 in the last 90 days. Company insiders own 23.30% of the company’s stock.

Several large investors have recently modified their holdings of BLCM. Principal Financial Group Inc. boosted its stake in shares of Bellicum Pharmaceuticals by 0.7% in the first quarter. Principal Financial Group Inc. now owns 83,338 shares of the biopharmaceutical company’s stock worth $1,029,000 after buying an additional 610 shares during the last quarter. American International Group Inc. boosted its stake in shares of Bellicum Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 12,902 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 852 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Bellicum Pharmaceuticals by 1.0% in the first quarter. Bank of New York Mellon Corp now owns 95,934 shares of the biopharmaceutical company’s stock worth $1,184,000 after buying an additional 935 shares during the last quarter. Teachers Advisors LLC boosted its stake in shares of Bellicum Pharmaceuticals by 5.5% in the fourth quarter. Teachers Advisors LLC now owns 35,608 shares of the biopharmaceutical company’s stock worth $485,000 after buying an additional 1,844 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its stake in shares of Bellicum Pharmaceuticals by 5.9% in the first quarter. Schwab Charles Investment Management Inc. now owns 73,666 shares of the biopharmaceutical company’s stock worth $910,000 after buying an additional 4,104 shares during the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

WARNING: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/bellicum-pharmaceuticals-inc-nasdaqblcm-releases-quarterly-earnings-results-misses-estimates-by-0-09-eps/1466607.html.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Earnings History for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.